This site is intended for U.S. health care professionals.
Important Safety Information and Indications
Neutropenia was the most frequently reported adverse reaction in PALOMA-2 (80%) and PALOMA-3 (83%). In PALOMA-2, Grade 3 (56%) or 4 (10%) decreased neutrophil counts were reported in patients receiving IBRANCE plus letrozole. In PALOMA-3, Grade 3 (55%) or Grade 4 (11%) decreased neutrophil counts were reported in patients receiving IBRANCE plus fulvestrant. Febrile neutropenia has been reported in 1.8% of patients exposed to IBRANCE across PALOMA-2 and PALOMA-3. One death due to neutropenic sepsis was observed in PALOMA-3. Inform patients to promptly report any fever.
Monitor complete blood count prior to starting IBRANCE, at the beginning of each cycle, on Day 15 of first 2 cycles and as clinically indicated. Dose interruption, dose reduction, or delay in starting treatment cycles is recommended for patients who develop Grade 3 or 4 neutropenia.
Based on the mechanism of action, IBRANCE can cause fetal harm. Advise females of reproductive potential to use effective contraception during IBRANCE treatment and for at least 3 weeks after the last dose. IBRANCE may impair fertility in males and has the potential to cause genotoxicity. Advise male patients with female partners of reproductive potential to use effective contraception during IBRANCE treatment and for 3 months after the last dose. Advise females to inform their healthcare provider of a known or suspected pregnancy. Advise women not to breastfeed during IBRANCE treatment and for 3 weeks after the last dose because of the potential for serious adverse reactions in nursing infants.
The most common adverse reactions (≥10%) of any grade reported in PALOMA-2 for IBRANCE plus letrozole vs placebo plus letrozole were neutropenia (80% vs 6%), infections (60% vs 42%), leukopenia (39% vs 2%), fatigue (37% vs 28%), nausea (35% vs 26%), alopecia (33% vs 16%), stomatitis (30% vs 14%), diarrhea (26% vs 19%), anemia (24% vs 9%), rash (18% vs 12%), asthenia (17% vs 12%), thrombocytopenia (16% vs 1%), vomiting (16% vs 17%), decreased appetite (15% vs 9%), dry skin (12% vs 6%), pyrexia (12% vs 9%), and dysgeusia (10% vs 5%).
The most frequently reported Grade ≥3 adverse reactions (≥5%) in PALOMA-2 for IBRANCE plus letrozole vs placebo plus letrozole were neutropenia (66% vs 2%), leukopenia (25% vs 0%), infections (7% vs 3%), and anemia (5% vs 2%).
Lab abnormalities of any grade occurring in PALOMA-2 for IBRANCE plus letrozole vs placebo plus letrozole were decreased WBC (97% vs 25%), decreased neutrophils (95% vs 20%), anemia (78% vs 42%), decreased platelets (63% vs 14%), increased aspartate aminotransferase (52% vs 34%), and increased alanine aminotransferase (43% vs 30%).
The most common adverse reactions (≥10%) of any grade reported in PALOMA-3 for IBRANCE plus fulvestrant vs placebo plus fulvestrant were neutropenia (83% vs 4%), leukopenia (53% vs 5%), infections (47% vs 31%), fatigue (41% vs 29%), nausea (34% vs 28%), anemia (30% vs 13%), stomatitis (28% vs 13%), diarrhea (24% vs 19%), thrombocytopenia (23% vs 0%), vomiting (19% vs 15%), alopecia (18% vs 6%), rash (17% vs 6%), decreased appetite (16% vs 8%), and pyrexia (13% vs 5%).
The most frequently reported Grade ≥3 adverse reactions (≥5%) in PALOMA-3 for IBRANCE plus fulvestrant vs placebo plus fulvestrant were neutropenia (66% vs 1%) and leukopenia (31% vs 2%).
Lab abnormalities of any grade occurring in PALOMA-3 for IBRANCE plus fulvestrant vs placebo plus fulvestrant were decreased WBC (99% vs 26%), decreased neutrophils (96% vs 14%), anemia (78% vs 40%), decreased platelets (62% vs 10%), increased aspartate aminotransferase (43% vs 48%), and increased alanine aminotransferase (36% vs 34%).
Avoid concurrent use of strong CYP3A inhibitors. If patients must be administered a strong CYP3A inhibitor, reduce the IBRANCE dose to 75 mg/day. If the strong inhibitor is discontinued, increase the IBRANCE dose (after 3-5 half-lives of the inhibitor) to the dose used prior to the initiation of the strong CYP3A inhibitor. Grapefruit or grapefruit juice may increase plasma concentrations of IBRANCE and should be avoided. Avoid concomitant use of strong CYP3A inducers. The dose of sensitive CYP3A substrates with a narrow therapeutic index may need to be reduced as IBRANCE may increase their exposure.
IBRANCE has not been studied in patients with moderate to severe hepatic impairment or in patients with severe renal impairment (CrCl <30 mL/min).
IBRANCE is indicated for the treatment of hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) advanced or metastatic breast cancer in combination with:
- an aromatase inhibitor as initial endocrine-based therapy in postmenopausal women, or
- fulvestrant in women with disease progression following endocrine therapy
PALOMA-2 and PALOMA-1 Trial Designs
Based on the data from PALOMA-1, IBRANCE received accelerated approval from the US FDA3
- PALOMA-1 was a 1:1 randomized, open-label, Phase 2 trial4
- PALOMA-1 evaluated the efficacy and safety of IBRANCE + letrozole compared with letrozole alone as initial endocrine-based therapy for postmenopausal women with ER+/HER2- MBC (N=165)4
- IBRANCE 125 mg PO was given once daily 3 weeks on, 1 week off + letrozole 2.5 mg once daily vs letrozole alone4
ER=estrogen receptor; MBC=metastatic breast cancer.
EXPANDED FIRST-LINE INDICATION
IBRANCE was studied with letrozole but is FDA approved for use with any aromatase inhibitor for postmenopausal women with HR+/HER2- MBC
2. Data on File. Pfizer Inc, New York, NY.
3. Pfizer receives U.S. FDA accelerated approval of IBRANCE® (palbociclib) [news release]. New York, NY: Pfizer Inc; February 3, 2015. http://www.pfizer.com/news/press-release/press-release-detail/pfizer_receives_u_s_fda_accelerated_approval_of_ibrance_palbociclib. Accessed May 8, 2017.
4. Finn RS, Crown JP, Lang I, et al. The cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1/TRIO-18): a randomised phase 2 study. Lancet Oncol. 2015;16(1):25-35.
IBRANCE + letrozole was evaluated in a variety of first-line patients1
PALOMA-2: Selected baseline patient characteristicsPatients receiving IBRANCE + letrozole varied in age, disease site, disease-free interval, and treatment history.*
There were no significant differences in baseline characteristics between the 2 treatment arms for age, disease site, disease-free interval, and prior hormonal therapy use in the adjuvant setting (IBRANCE + letrozole n=444; placebo + letrozole n=222).
*Patients were stratified by site of disease, by disease-free interval since completion of prior neoadjuvant or adjuvant therapy, and by the nature of prior neoadjuvant or adjuvant anticancer treatment received prior to their diagnosis of advanced breast cancer.2
†Disease-free interval was defined as the time from neoadjuvant or adjuvant therapy to recurrence.1
‡Patients who had received anastrozole or letrozole as a component of their adjuvant or neoadjuvant therapy were excluded from the study if they had disease progression while receiving the therapy or within 12 months after completing the therapy. 48% of patients had received chemotherapy in the neoadjuvant or adjuvant setting.1
PALOMA-1: Selected baseline patient characteristics2
- Age: <65 years (n=47), 56%; ≥65 years (n=37), 44%
- Disease site: Visceral (n=39), 46.4%; bone only (n=17), 20.2%; other§ (n=28), 33.3%
- Disease-free interval||: >12 months (n=37), 44.1%; ≤12 months (n=47), 56.0%
- Systemic therapy prior to MBC diagnosis: No (n=44), 52.4%; Yes (n=40), 47.6%
MBC=metastatic breast cancer.
§Other is defined as bone with other nonvisceral disease site or other disease site alone. Bone was the site of disease in 72.6% of patients in the IBRANCE + letrozole arm vs 76.5% in the letrozole alone arm.2
||Disease-free interval was defined as the time from the end of adjuvant treatment to disease recurrence or de novo advanced disease.2
Efficacy and Safety Profile
PALOMA-3 Patient Characteristics
2. Data on file. Pfizer Inc, New York, NY.